Levetiracetam

CHEMBL1286 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

170.2 g/mol

LogP

-0.3

Phase

4

An anticonvulsant used to treat focal and generalized seizures in epilepsy, and studied for mood stabilization in bipolar disorder. It works through a unique mechanism involving synaptic vesicle protein 2A (SV2A) to reduce abnormal neuronal activity.

Moleküler Ağırlık

170,2100 g/mol

LogP

-0,30

TPSA

63,40 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Thyroid Cancer Glaucoma Pain Management Non-Small Cell Lung Cancer Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Multiple Sclerosis Stroke Lymphoma Chronic Pain Malaria Leukemia

Etki Mekanizması

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CC[C@@H](C(N)=O)N1CCCC1=O

InChI

InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1

Molecular Formula

C8H14N2O2

HBD / HBA

1 / 2

Döndürülebilir Bağlar

3

Ağır Atomlar

12

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

An anticonvulsant used to treat focal and generalized seizures in epilepsy, and studied for mood stabilization in bipolar disorder. It works through a unique mechanism involving synaptic vesicle protein 2A (SV2A) to reduce abnormal neuronal activity.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Levetiracetam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1286. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5284583. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Levetiracetam PillFYI'da

Yapı

Hızlı Veriler

Formül: C8H14N2O2
Eş Anlamlılar: 10

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.